A U.S. Food and Drug Administration advisory panel vote on whether to recommend approval of the first oral medication for type 1 diabetes ended in an 8-8 tie Thursday.
Latest Diabetes News
Despite that result, the FDA is expected to decide by the end of March whether the drug — sotagliflozin (Zynquista) should be made available in the United States, The New York Times reported.
Some of the advisory panel members voted against Zynquista because it carries an increased risk of a dangerous condition called diabetic ketoacidosis, which occurs when the body doesn’t get enough insulin, The Times reported.
Drug makers Sanofi and Lexicon Pharmaceuticals said they’ll continue to work with the FDA through the review process for the drug.
Copyright © 2018 HealthDay. All rights reserved.